Arterial thromboembolism and acute coronary syndrome in patients with malignant diseases. Analytical review. Part 1
https://doi.org/10.52727/2078-256X-2025-21-1-92-104
Abstract
Arterial thromboembolic complications are rare in cancer patients. Malignant neoplasms and antitumor therapy contribute to an increased risk of arterial thromboembolism, ischemic stroke, and myocardial infarction. The development of arterial thromboembolism in people without a history of cancer may be a harbinger of as yet undetected malignancies. Understanding the process of arterial thromboembolism is an important prerequisite for the proper management of patients with cancer during and after treatment in order to prevent life-threatening complications.
About the Authors
D. V. Kozlov
State Budgetary Institution of Healthcare of the City of Moscow “City Clinical Hospital named after F.I. Inozemtsev of the Moscow City Health Department”
Russian Federation
Russian Federation
Denis V. Kozlov, candidate of medical sciences, cardiovascular surgeon
1, Fortunatovskaya st., Moscow, 105187
A. I. Zagorulko
Branch “Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow City Health Department”; Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia named after Patrice Lumumba”
Russian Federation
Russian Federation
Alexey I. Zagorulko, candidate of medical sciences, head of the department of X-ray endovascular methods of diagnosis and treatment No. 2
18A, bld. 7, Zagorodnoye highw., Moscow, 117152
6, Miklukho-Maklaya st., Moscow, 117198
G. P. Nistratov
Branch “Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow City Health Department”
Russian Federation
Russian Federation
Grigory P. Nistratov, candidate of medical sciences, doctor of department of X-ray endovascular methods of diagnosis and treatment No. 2
18A, bld. 7, Zagorodnoye highw., Moscow, 117152
S. P. Rykov
Branch “Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow City Health Department”
Russian Federation
Russian Federation
Stanislav P. Rykov, doctor at the department of X-ray endovascular methods of diagnosis and treatment No. 2
18A, bld. 7, Zagorodnoye highw., Moscow, 117152
References
1. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Elkind M.S., Panageas K.S., DeAngelis L.M. OC-02 – Risk of arterial thromboembolism in patients with breast cancer. Thromb. Res., 2016; 140, Suppl 1: S169. doi: 10.1016/S0049-3848(16)30119-0
2. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of arterial thromboembolism in patients with cancer. J. Am. Coll. Cardiol., 2017; 70 (8): 926–938. doi: 10.1016/j.jacc.2017.06.047
3. Grilz E., Königsbrügge O., Posch F., Schmidinger M., Pirker R., Lang I.M., Pabinger I., Ay C. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica, 2018; 103 (9): 1549–1556. doi: 10.3324/haematol.2018.192419
4. Mulder F.I., Horváth-Puhó E., van Es N., Pedersen L., Büller H.R., Bøtker H.E., Sørensen H.T. Arterial thromboembolism in cancer patients: a danish population-based cohort study. JACC CardioOncol., 2021; 3 (2): 205–218. doi: 10.1016/j.jac-cao.2021.02.007
5. Qin Y., Zhang L., Liang X., Sun X., Wang N., Yuan M. Wang Q., Wu D. Venous and arterial thromboembolism in patients with metastatic lung cancer. Clin. Appl. Thromb. Hemost., 2023; 29: 10760296231159121. doi: 10.1177/10760296231159121
6. Cheong M.A., Leader A. Cancer and arterial thrombosis: therapeutic options. Res. Pract. Thromb. Haemost., 2024; 8 (3): 102393. https://doi.org/10.1016/j.rpth.2024.102393
7. Xu Y., Mallity C., Collins E., Siegal D.M., Wang T.F., Carrier M. Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumor site: a systematic review and meta-analysis of randomized trials. Eur. Heart J. Cardiovasc. Pharmacother., 2024; pvae068. doi: 10.1093/ehjcvp/pvae068
8. Zöller B., Ji J., Sundquist J., Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur. J. Cancer, 2012; 48 (1): 121–128. doi: 10.1016/j.ejca.2011.09.015
9. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Tagawa S.T., Panageas K.S., DeAngelis L.M. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood, 2019; 133 (8): 781–789. doi: 10.1182/blood-2018-06-860874
10. Starr D.S., Lawrie G.M., Morris G.C. Jr. Unusual presentation of bronchogenic carcinoma: Case report and review of the literature. Cancer, 1981; 47: 398–401. doi: 1002/1097-0142(19810115)47:2<398::aid-cncr2820470230>3.0.co;2-r
11. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol., 2006; 24 (3): 484–490. doi: 10.1200/JCO.2005.03.8877
12. Marković M., Davidović L., Mikić A., Djorić P., Putnik S. Rare forms of peripheral arterial embolism: review of 11 cases. Vascular, 2005; 13: 222–229. doi: 10. 1258/rsmvasc.13.4.222
13. Navi B.B., Singer S., Merkler A.E., Cheng N.T., Stone J.B., Kamel H., Iadecola C., Elkind M.S., DeAngelis L.M. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology, 2014; 83 (1): 26–33. doi: 10.1212/WNL.0000000000000539
14. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost., 2007; 5 (3): 632–634. doi: 10.1111/j.1538-7836.2007.02374.x
15. Gon Y., Morishima T., Kawano T., Okazaki S., Todo K., Sasaki T., Mochizuki H., Miyashiro I. Arterial thromboembolism in Japanese patients with cancer: Incidence, predictors, and survival impact. JACC CardioOncol., 2024; 6 (2): 283–297. doi: 10.1016/j.jaccao.2024.01.006
16. Wang J., Kim Y.D., Kim C.H. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin. Proc., 2021; 96 (3): 592–600. doi: 10.1016/j.mayocp.2020.05.045
17. Bollen E.C., van Duin C.J., van Noord J.A., Janssen J.G., Theunissen P.H. Tumor embolus in lung surgery. A case report and review of the literature. Eur. J. Cardiothorac. Surg., 1993; 7 (2): 104–106. doi: 10.1016/1010-7940(93)90190-m
18. Price L.C., Seckl M.J., Dorfmüller P., Wort S.J. Tumoral pulmonary hypertension. Eur. Respir. Rev., 2019; 28 (151): 180065. doi: 10.1183/16000617.0065-2018
19. Wang F., Gulati R., Lennon R.J., Lewis B.R., Park J., Sandhu G.S., Wright R.S., Lerman A., Herrmann J. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute st-segment elevation myocardial infarction. Mayo Clin. Proc., 2016; 91 (12): 1680–1692. doi: 10.1016/j.mayocp.2016.06.029
20. Sundbøll J., Veres K., Horváth-Puhу E., Adelborg K., Sørensen H.T. Risk and prognosis of cancer after lower limb arterial thrombosis. Circulation, 2018; 138 (7): 669–677. doi: 10.1161/CIRCULATIONAHA.117.032617
21. Kaschwich M., Peters F., Hischke S., Rieß H.C., Gansel M., Marschall U., L’Hoest H., Heidemann F., Debus E.S., Acar L., Kreutzburg T., Behrendt C.A. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease – a health insurance claims data analysis. Vasa, 2020; 49 (6): 493–499. doi: 10.1024/0301-1526/a000901
22. Lee J.M., Yoon C.H. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ. J., 2012; 42 (7): 487–491. doi: 10.4070/kcj.2012.42.7.487
23. Ganatra S., Sharma A., Levy M.S. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc. Interv., 2017; 10 (22): 2334–2337. doi: 10.1016/j.jcin.2017.06.068
24. Yu J., Li A., Laureano M., Crowther M. Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thromb. Res., 2019; 184: 16–23. doi: 10.1016/j.thromres.2019.10.004
25. Canale M.L., Bisceglia I., Lestuzzi C., Parrini I.; ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res., 2019; 39 (9): 4619–4625. doi: 10.21873/anticanres.13642
26. Qi W.X., Shen Z., Tang L.N., Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit. Rev. Oncol. Hematol., 2014; 92 (2): 71–82. doi: 10.1016/j.critrev-onc.2014.04.004
27. McBane R.D. 2nd. Arterial thrombosis and cancer: implications for screening and risk modification. Mayo Clin. Proc., 2021; 96 (3): 526–528. doi: 10.1016/j.mayocp.2021.01.013
28. Quartermaine C., Ghazi S.M., Yasin A., Awan F.T., Fradley M., Wiczer T., Kalathoor S., Ferdousi M, Krishan S., Habib A., Shaaban A., Kola-Kehinde O., Kittai A.S., Rogers K.A., Grever M., Ruz P., Bhat S., Dickerson T., Byrd J.C., Woyach J., Addison D. Cardiovascular toxicities of BTK Inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology stateof-the-art review. JACC CardioOncol., 2023; 5 (5): 570–590. doi: 10.1016/j.jaccao.2023.09.002
29. Enderoff E., Kirschner P.A. Massive tumor embolism during pulmonary surgery. J. Thorac. Cardiovasc. Surg., 1962; 44: 528–535.
30. Falanga A., Schieppati F., Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin. Thromb. Hemost., 2015; 41 (7): 756–764. doi: 10.1055/s-0035-1564040
31. Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer. Res., 2009; 15 (22): 6830–6840. doi: 10.1158/1078-0432.CCR-09-0371
32. Grover S.P., Mackman N. Tissue factor: An essential mediator of hemostasis and trigger of thrombosis. Arterioscler. Thromb. Vasc. Biol., 2018; 38 (4): 709–725. doi: 10.1161/Atvbaha.117.309846
33. Laridan E., Martinod K., de Meyer S.F. Neutrophil extracellular traps in arterial and venous thrombosis. Semin. Thromb. Hemost., 2019; 45 (1): 86–93. doi: 10.1055/s-0038-1677040
34. Moschonas I.C., Tselepis A.D. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis, 2019; 288: 9–16. doi: 10.1016/j.atherosclerosis.2019.06.919
35. Massberg S., Grahl L., von Bruehl M.L., Manukyan D., Pfeiler S., Goosmann C., Brinkmann V., Lorenz M., Bidzhekov K., Khandagale A.B., Konrad I., Kennerknecht E., Reges K., Holdenrieder S., Braun S., Reinhardt C., Spannagl M., Preissner K.T., Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med., 2010; 16 (8): 887–896. doi: 10.1038/nm.2184
36. Thеlin C., Demers M., Blomgren B., Wong S.L., von Arbin M., von Heijne A., Laska A.C., Wallén H., Wagner D.D., Aspberg S. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb. Res., 2016; 139: 56–64. doi: 10.1016/j.thromres.2016.01.009
37. Grover S.P., Hisada Y.M., Kasthuri R.S., Reeves B.N., Mackman N. Cancer therapy-associated thrombosis. Arterioscler. Thromb. Vasc. Biol., 2021; 41 (4): 1291– 1305. doi: 10.1161/ATVBAHA.120.314378
38. Zhu J., Chen Y., Zhang Y., Wang W., Wang Y., Lu Zh., Zhang Yu., Lei H., Li D., Long B., Liu H. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Med., 2023; 12: 118531–18541. doi: 10.1002/cam4.6455
39. Alexandre J., Salem J.E., Moslehi J., Sassier M., Ropert C., Cautela J., Thuny F., Ederhy S., Cohen A., Damaj G., Vilque J.P., Plane A.F., Legallois D., Champ-Rigot L., Milliez P., Funck-Brentano C., Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur. Heart J. Cardiovasc. Pharmacother., 2021; 7 (4): 312–320. doi: 10.1093/ehjcvp/pvaa037
40. Salem J.E., Manouchehri A., Bretagne M., Lebrun-Vignes B., Groarke J.D., Johnson D.B., Yang T., Reddy N.M., Funck-Brentano C., Brown J.R., Roden D.M., Moslehi J.J. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol., 2019; 74 (13): 1667–1678. doi: 10.1016/j.jacc.2019.07.056
41. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. RUSSCO Practical recommendations. Malignant tumors, 2023; 13 (2): 86–111. (In Russ.)]. doi: 10.18027/2224-5057-2023-13-3s2-2-86-111
42. Valent P., Hadzijusufovic E., Schernthaner G.H., Wolf D., Rea D., le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015; 125 (6): 901–906. doi: 10.1182/blood-2014-09-594432
43. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., Kolesnik R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 2001; 293 (5528): 293–297. doi: 10.1126/science.1060191
44. Texakalidis P., Giannopoulos S., Tsouknidas I., Song S., Rivet D., Reiter E., Reavey-Cantwell J. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: A systematic review and meta-analysis. Head Neck., 2020; 42 (5): 1077–1088. doi: 10.1002/hed.26102
45. Murphy E.S., Xie H., Merchant T.E., Yu J.S., Chao S.T., Suh J.H. Review of cranial radiotherapy-induced vasculopathy. J. Neurooncol., 2015; 122 (3): 421–429. doi: 10.1007/s11060-015-1732-2
46. Feldman S., Gupta D., Navi B.B., Grace Ho K.W., Willeit P., Devlin S., Bolton K.L., Arcila M.E., Mantha S. Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer. JACC CardioOncol., 2023; 5 (2): 246–255. doi: 10.1016/j.jaccao.2023.01.009
47. Buijs J.T., Versteeg H.H. Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb. Res., 2020; 191 Suppl 1: S43–S49. doi: 10.1016/S0049-3848(20)30396-0
48. Al-Samkari H., Leiva O., Dagogo-Jack I., Shaw A., Lennerz J., Iafrate A.J., Bendapudi P.K., Connors J.M. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J. Thorac. Oncol., 2020; 15 (9): 1497–1506. doi: 10.1016/j.jtho.2020.04.033
49. Rak J., Milsom C., May L., Klement P., Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost., 2006; 32 (1): 54–70. doi: 10.1055/s-2006-933341
50. Vavlukis M., Kotlar I., Chaparoska E., Antova E., Kedev S. Diffuse arterial thrombosis as a first manifestation of occult malignancy. Case Rep. Med., 2016; 2016: 1658392. doi: 10.1155/2016/1658392
51. Selvik H.A., Thomassen L., Bjerkreim A.T., Næss H. Cancer-associated stroke: The Bergen NORSTROKE study. Cerebrovasc. Dis. Extra, 2015; 5 (3): 107–113. doi: 10.1159/000440730
52. Qureshi A.I., Malik A.A., Saeed O., Adil M.M., Rodriguez G.J., Suri M.F. Incident cancer in a cohort of 3,247 cancer diagnosis free ischemic stroke patients. Cerebrovasc. Dis., 2015; 39 (5-6): 262–268. doi: 10.1159/000375154
53. Haugnes H.S., Wethal T., Aass N., Dahl O., Klepp O., Langberg C.W., Wilsgaard T., Bremnes R.M., Fossе S.D. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J. Clin. Oncol., 2010; 28 (30): 4649–4657. doi: 10.1200/JCO.2010.29.9362
54. Ueki Y., Vögeli B., Karagiannis A., Zanchin T., Zanchin C., Rhyner D., Otsuka T., Praz F., Siontis G.C.M, Moro C., Stortecky S., Billinger M., Valgimigli M., Pilgrim T., Windecker S., Suter T., Räber L. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol., 2019; 1 (2): 145–155. doi: 10.1016/j.jaccao.2019.11.001
55. Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P., de Belder M.A., Kwok C.S., Rashid M., Fischman D.L., Mamas M.A. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J., 2019; 40 (22): 1790–1800. doi: 10.1093/eurheartj/ehy769
56. Lyon A.R., Lуpez-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J., 2022; 43 (41): 4229–4361. doi: 10.1093/eurheartj/ehac244
57. Gross C.M., Posch M.G., Geier C., Olthoff H., Krämer J., Dechend R., Dietz R., Ozcelik C. Subacute coronary stent thrombosis in cancer patients. J. Am. Coll. Cardiol., 2008; 51 (12): 1232–1233. doi: 10.1016/j.jacc.2007.11.061
58. Bianco M., D’ascenzo F., Raposeiras Roubin S., Kinnaird T., Peyracchia M., Ariza-Solé A., Cerrato E., Manzano-Fernández S., Gravinese C., Templin C., Destefanis P., Velicki L., Luciano A., Xanthopoulou I., Rinaldi M., Rognoni A., Varbella F., Boccuzzi G., Omedè P., Montabone A., Bernardi A., Taha S., Rossini R., Durante A., Gili S., Magnani G., Autelli M., Grosso A., Blanco P.F., Giustetto C., Garay A. Quadri G., Queija B.C., Srdanovic I., Paz R.C., Fernández M.C., Pousa I.M., Gallo D., Morbiducci U., Dominguez-Rodriguez A., Lopez-Cuenca Á., Cequier A., Alexopoulos D., Iсiguez-Romo A., Pozzi R., Assi E.A., Valgimigli M. Comparative external validation of the PRECISEDAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int. J. Cardiol., 2020; 301: 200–206. doi: 10.1016/j.ijcard.2019.11.132
59. Bharadwaj A., Potts J., Mohamed M.O., Parwani P., Swamy P., Lopez-Mattei J.C., Rashid M., Kwok C.S., Fischman D.L., Vassiliou V.S., Freeman Ph., Michos E.D., Mamas M.A. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur. Heart J., 2020; 41 (23): 2183–2193. doi: 10.1093/eurheartj/ehz851
60. Duarte C.W., Lindner V., Francis S.A., Schoormans D. Visualization of cancer and cardiovascular disease co-occurrence with network methods. JCO Clin. Cancer Inform., 2017; 1: 1–12. doi: 10.1200/CCI.16.00071
61. Milazzo V., Cosentino N., Campodonico J., Lucci C., Cardinale D., Cipolla C.M., Marenzi G. Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. J. Clin. Med., 2020; 9 (11): 3642. doi: 10.3390/jcm9113642
62. Ederhy S., Cohen A., Boccara F., Puymirat E., Aissaoui N., Elbaz M., Bonnefoy-Cudraz E., Druelles P., Andrieu S., Angoulvant D., Furber A., Ferrières J., Schiele F., Cottin Y., Simon T., Danchin N. FASTMI investigators. In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Arch. Cardiovasc. Dis., 2019; 112 (11): 657–669. doi: 10.1016/j.acvd.2019.06.012
63. Gevaert S.A., Halvorsen S., Sinnaeve P.R., Sambola A., Gulati G., Lancellotti P., van der Meer P., Lyon A.R., Farmakis D., Lee G., Boriani G., Wechalekar A., Okines A., Asteggiano R. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur. Heart J. Acute Cardiovasc. Care, 2021; 10 (8): 947–959. doi: 10.1093/ehjacc/zuab056
64. Pushparaji B., Donisan T., Balanescu D.V., Park J.K., Monlezun D.J., Ali A., Inanc I.H., Caballero J., Cilingiroglu M., Marmagkiolis K., Iliescu C. Coronary revascularization in patients with cancer. Curr. Treat. Options. Cardiovasc. Med., 2023; 25 (6): 143–158. doi: 10.1007/s11936-023-00982-9
65. Yusuf S.W., Daraban N., Abbasi N., Lei X., Durand J.B., Daher I.N. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin. Cardiol., 2012; 35 (7): 443–450. doi: 10.1002/clc.22007
66. Pothineni N.V., Shah N.N., Rochlani Y., Saad M., Kovelamudi S., Marmagkiolis K., Bhatti S., Cilingiroglu M., Aronow W.S., Hakeem A. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann. Transl. Med., 2017; 5 (24): 482. doi: 10.21037/atm.2017.11.29
67. Roule V., Verdier L., Blanchart K., Ardouin P., Lemaitre A., Bignon M., Sabatier R., Alexandre J., Beygui F. Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. BMC Cardiovasc. Disord., 2020; 20 (1): 38. doi: 10.1186/s12872-020-01352-0
68. Iliescu C.A., Grines C.L., Herrmann J., Yang E.H., Cilingiroglu M., Charitakis K., Hakeem A., Toutouzas K.P., Leesar M.A., Marmagkiolis K. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc. Interv., 2016; 87 (5): E202–223. doi: 10.1002/ccd.26379
Review
For citations:
Kozlov D.V., Zagorulko A.I., Nistratov G.P., Rykov S.P. Arterial thromboembolism and acute coronary syndrome in patients with malignant diseases. Analytical review. Part 1. Ateroscleroz. 2025;21(1):92-104. (In Russ.) https://doi.org/10.52727/2078-256X-2025-21-1-92-104
Views:
101
Email this article 